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Abstract
Obesity	and	hypertension	are	prevalent	comorbidities	in	heart	failure	with	preserved	
ejection	fraction.	To	clarify	if	and	how	interaction	between	these	comorbidities	con-
tributes	 to	 development	 of	 diastolic	 dysfunction,	 lean	 and	 obese	 ZSF1	 rats	were	
treated	with	deoxycorticosterone	acetate	implants	and	a	high-salt	diet	(DS)	to	induce	
severe	hypertension,	or	with	placebo.	 In	 addition	 to	echocardiographic,	metabolic	
and	hemodynamic	analyses,	immunohistochemistry	and	RNAseq	were	performed	on	
left	ventricular	tissue.	Obesity	negatively	affected	cardiac	output,	led	to	an	elevated	
E/e’	ratio	and	mildly	reduced	ejection	fraction.	DS-induced	hypertension	did	not	af-
fect	cardiac	output	and	minimally	elevated	E/e’	ratio.	Diastolic	derangements	in	pla-
cebo-treated	obese	 rats	developed	 in	absence	of	 inflammation	and	 fibrosis,	yet	 in	
presence	of	oxidative	stress	and	hypertrophic	remodelling.	In	contrast,	hypertension	
triggered	apoptosis,	inflammation	and	fibrosis,	with	limited	synergy	of	the	comorbidi-
ties	observed	for	inflammation	and	fibrosis.	Transcriptional	data	suggested	that	these	
comorbidities	exerted	opposite	effects	on	mitochondrial	function.	In	placebo-treated	
obese	rats,	genes	involved	in	fatty	acid	metabolism	were	up-regulated,	whereas	DS-
induced	a	down-regulation	of	genes	involved	in	oxidative	phosphorylation.	Overall,	
limited	 interaction	was	 observed	 between	 these	 comorbidities	 in	 development	 of	
diastolic	dysfunction.	Importantly,	differences	in	obesity-	and	hypertension-induced	
cardiac	remodelling	emphasize	the	necessity	for	comorbidity-specific	phenotypical	
characterization.
K E Y W O R D S
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1  | INTRODUC TION
The	chronic	and	progressive	condition,	in	which	the	heart	is	unable	
to	maintain	cardiac	output	commensurate	with	the	body's	require-
ments,	is	referred	to	as	heart	failure	(HF).	Based	on	ejection	fraction,	
HF	can	be	divided	 into	HF	with	reduced	ejection	fraction	(HFrEF),	
marked	by	 the	 inability	 to	adequately	contract	during	systole,	and	
HF	with	preserved	ejection	 fraction	 (HFpEF).	HFpEF	 is	 associated	
with	 impaired	 cardiac	 relaxation	 and	 increased	 passive	 cardiac	
stiffness,	 resulting	 in	elevated	end-diastolic	pressure	and	 impaired	
left	ventricular	(LV)	filling.1	HFpEF	accounts	for	over	50%	of	all	HF	
cases	in	Europe	and	the	United	States	of	America,	yet	currently	no	
effective	treatment	is	available	for	this	specific	form	of	HF.1
This	 lack	 of	 evidence-based	 treatment	 options	 might	 find	 its	
origin	 in	 the	 complex,	 multifactorial	 disease	 aetiology	 of	 HFpEF.	
Development	and	progression	of	HFpEF	 is	associated	with	a	high	
prevalence	 of	 non-cardiac	 comorbidities	 and	 in	 previous	 studies	
it	was	proposed	that	these	comorbidities	could	provoke	a	state	of	
chronic	 systemic	 inflammation,	 leading	 to	 coronary	 microvascu-
lar	 dysfunction,	 oxidative	 stress,	 enhanced	 cardiomyocyte	 stiff-
ness	and	myocardial	 fibrosis.2	Obesity	and	hypertension	are	both	
highly	prevalent	 (84%	and	60%-80%,	 respectively)	 among	HFpEF	
patients.3,4	 It	has	been	demonstrated	that	both	comorbidities	can	
individually	contribute	 to	development	of	diastolic	dysfunction	 in	
rodent	 models.	 For	 example,	 deoxycorticosterone	 acetate-	 and	
salt-induced	 hypertensive	 rats	 developed	 perivascular	 fibrosis,	
and	concentric	cardiac	hypertrophy	accompanied	by	diastolic	dys-
function	in	addition	to	hypertension.5,6	Similarly,	in	leptin-deficient	
murine	 obesity	models,	 ob/ob	mice	were	 shown	 to	 develop	 con-
centric	cardiac	remodelling	with	increased	cardiomyocyte	size	and	
diastolic	dysfunction,7,8	secondary	to	obesity	and	type	2	diabetes.9 
Importantly,	it	is	estimated	that	at	least	75%	of	the	incidence	of	hy-
pertension	in	the	human	population	is	related	to	obesity,10	and	both	
comorbidities	thus	often	present	together.	The	current	consensus	
is	that	metabolic	and	hypertensive	disease,	like	other	HFpEF-asso-
ciated	comorbidities,	contribute	to	the	systemic	state	of	inflamma-
tion,2	 and	 as	 such,	 potentially	 act	 synergistically	 in	 development	
and	progression	of	diastolic	dysfunction.	However,	direct	evidence	
for	such	a	synergistic	relation	is	lacking.	More	insight	in	the	putative	
synergistic	effects	might	not	only	provide	a	better	understanding	
of	the	pathogenesis	of	HFpEF	itself,	but	could	also	lead	to	novel	in-
sights	in	the	poor	performance	of	antihypertensive	drug	treatment	
alone	 in	 reducing	morbidity	or	mortality	 in	subsets	of	 (obese)	pa-
tients	with	HFpEF.11
Here,	we	tested	the	hypothesis	that	metabolic	and	hypertensive	
disease	 act	 synergistically	 in	 development	 and/or	 progression	 of	
HFpEF.	For	this	purpose,	male	 lean	and	obese	ZSF1	rats,	of	which	
the	 latter	were	previously	 shown	 to	develop	diastolic	dysfunction	
between	week	10	and	20	of	natural	ageing,12,13	were	studied	from	
12	weeks	of	age.	Both	 lean	and	obese	 rats	were	 treated	with	de-
oxycorticosterone	acetate	 implants	plus	high-salt	 diet	 (DS)	or	pla-
cebo	from	19	to	26	weeks	of	age	to	induce	severe	hypertension.	DS	
treatment	was	limited	to	this	period	to	prevent	potential	progression	
to	 HFrEF.	 In	 addition	 to	 echocardiographic,	 metabolic	 and	 hemo-
dynamic	analyses,	 immunohistochemistry	and	RNAseq	on	LV	apex	
tissue	 was	 performed,	 which	 enabled	 us	 to	 dissect	 which	 patho-
physiological	and	 transcriptional	adaptations	were	associated	with	
obesity	and	its	associated	biochemical	aberrations,	and	which	adap-
tations	with	DS-induced	hypertension.
2  | METHODS
2.1 | Ethics
All	animal	studies	were	approved	by	the	Animal	Ethics	Committee	
of	the	University	of	Utrecht	(CCD:	AVD115002016462)	and	were	in	
accordance	with	the	Dutch	Codes	of	Practice	for	the	Care	and	Use	
of	 Animals	 for	 Scientific	 Purposes.	 Animal	 experiments	were	 per-
formed	according	to	ARRIVE	(Animal	Research:	Reporting	of	In	Vivo	
Experiments)	guidelines.
2.2 | Animal model
Nine-week-old	male	lean	(n	=	13)	and	obese	(n	=	13)	ZSF1	rats	were	
obtained	 from	 Charles	 River	 and	 housed	 in	 a	 temperature-	 and	
humidity-controlled	 environment	 with	 a	 12-hour	 light/dark	 cycle.	
Rats	had	access	to	water	and	standard	chow	(CRM-E;	Special	Diet	
Services)	ad	libitum.	Starting	at	12	weeks	until	26	weeks	of	age,	sys-
tolic	blood	pressure	(SBP)	measurements	via	tail-cuff	plethysmogra-
phy	were	obtained	every	2	weeks.	At	12	weeks	and	every	2	weeks	
from	 18	 to	 26	 weeks	 of	 age	 echocardiography	 was	 performed,	
whereas	 body	weight	was	measured	 every	week.	 At	 19	weeks	 of	
age,	lean	and	obese	rats	were	randomized	and	either	implanted	with	
a	deoxycorticosterone	acetate	pellet	(35	mg	in	lean,	50	mg	in	obese;	
Innovative	Research	of	America)	and	fed	a	high-salt	diet	(6%	NaCl)	
or	with	a	placebo	pellet	and	fed	a	normal	salt	diet.	At	week	26,	after	
the	last	measurements,	the	rats	were	terminated	via	exsanguination	
under	 deep	 anaesthesia	 and	 organs	were	 harvested	 and	weighed	
(Figure	1A).
2.3 | Echocardiographic evaluation
Rats	were	anesthetized	with	isoflurane	(3.5%-4%	for	induction	and	
2%-2.5%	 for	 maintenance).	 Transthoracic	 echocardiography	 was	
performed	with	a	digital	ultrasound	machine	 (model	Sonos	5500,	
Philips	Research)	 and	 a	 15-MHz	 linear	 array	 transducer	 (Hewlett	
Packard).	The	LV	long-axis	dimensions	were	recorded	by	2D	echo-
cardiography.	Two-dimensional	B-mode	cine	loops	were	recorded	
in	the	parasternal	long-axis	and	the	midpapillary	short-axis	views.	
Mitral	 flow	 velocity	 tracings	 were	 obtained	 with	 pulsed-wave	
Doppler	 above	 the	 mitral	 leaflets.	 Tissue	 Doppler	 imaging	 (TDI)	
was	used	to	obtain	early	(e’)	diastolic	velocity	at	the	medial	mitral	
annulus.	 The	 recordings	 were	 averaged	 from	 three	 consecutive	
heartbeats.
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2.4 | Statistics
Data	are	presented	as	mean	±	SEM.	Groups	were	compared	by	2-
way	ANOVA	or	2-way	ANOVA	for	repeated	measures,	followed	by	
Tukey	post	hoc	test,	as	appropriate.	Statistical	significance	was	ac-
cepted	when	P < .05.
Detailed	description	of	the	methods	is	available	in	the	Appendix	S1.
3  | RESULTS
3.1 | Model characteristics
Male	ZSF1	rats,	heterozygous	(lean)	or	homozygous	(obese)	for	leptin	
receptor	mutation,	were	 studied	 from	12	 to	26	weeks	of	 age.	Both	
lean	 and	 obese	 rats	 were	 treated	 with	 DS	 or	 placebo	 from	 19	 to	
26	weeks	of	age,	and	echocardiographic,	metabolic	and	hemodynamic	
analyses	were	performed	every	two	weeks	(Figure	1A).	ZSF1	rats	with	
leptin	receptor	deficiency	had	significantly	more	weight	gain	(Table	1).	
This	weight	gain	was	accompanied	by	elevated	blood	cholesterol	and	
triglycerides,	 with	 no	 distinction	 between	 placebo-	 and	 DS-treated	
obese	rats.	An	increase	in	blood	glucose	levels	was	observed	in	obese	
rats,	which	was	attenuated	by	DS	treatment.	As	anticipated,	DS	treat-
ment	led	to	markedly	increased	urinary	sodium	excretion.	This	sodium	
excretion	was	significantly	higher	in	DS-treated	obese	rats	compared	
with	DS-treated	 lean	rats,	but	was	not	different	when	corrected	for	
body	weight.	Systolic	blood	pressure	was	also	elevated	 in	both	 lean	
and	obese	DS-treated	rats,	with	a	synergistic	elevation	in	DS-treated	
obese	rats	(Figure	1B).
F I G U R E  1  Workflow	and	model	characteristics.	(A)	Graphical	workflow,	showing	that	male	lean	and	obese	ZSF1	rats	were	studied	from	
12	to	26	weeks	of	age.	Both	lean	and	obese	rats	were	treated	with	DS	or	placebo	from	19	to	26	weeks	of	age	to	trigger	severe	hypertension.	
Echocardiographic,	metabolic	and	hemodynamic	analyses	were	done	every	2	weeks,	till	sacrifice	at	the	age	of	26	weeks.	Longitudinal	plots	of	
(B)	systolic	blood	pressure	(mm	Hg),	(C)	ejection	fraction	(%)	and	(D)	E/e’	ratio.	n	=	6-7,	*	obese	vs	lean,	§	obese	+	DS	vs	lean	+	DS,	‡	lean	+	DS	
vs	lean,	†	obese	+	DS	vs	obese	P	<	.05.	(E)	Principal	component	analysis	of	expression	profiles	in	cardiac	tissue.	Symbols	denoting	subgroups	
panels	B-E	are	shown	in	panel	B.	(F-I)	Graphic	display	of	differential	gene	expression	in	which	log2FC	is	plotted	against	the	mean	of	
normalized	counts.	Red	dots	represent	the	differentially	expressed	genes	(FDR	<	0.1),	grey	dots	represent	non-differentially	expressed	genes
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Obesity,	 in	both	placebo-	and	DS-treated	rats,	caused	a	minor	
reduction	 in	 ejection	 fraction	 (EF),	 with	 the	 lowest	 EF	 (59%)	 ob-
served	in	the	DS-treated	obese	group	(Figure	1C).	Heart	rate	was	
reduced	 in	both	placebo-	 and	DS-treated	obese	 rats,	 and	 cardiac	
output	 (CO)	 tended	 to	be	 lower	 in	obese	vs	 lean	 (P	 =	 .08)	 and	 in	
obese	+	DS	vs	lean	+	DS	(P	=	.07).	When	corrected	for	body	mass	
(cardiac	 index),	placebo-	and	DS-treated	obese	 rats	appeared	un-
able	to	match	cardiac	output	to	body	mass.	Obesity	and	DS-induced	
hypertension	both	 tended	 to	 increase	 LV	weight	 (LVW)	 and	 total	
heart	weight	(HW),	but	a	significant	increase	was	only	observed	in	
presence	 of	 both	 comorbidities.	 Illustrative	 for	 diastolic	 dysfunc-
tion,	the	ratio	between	peak	velocity	of	early	mitral	inflow	and	early	
diastolic	mitral	annulus	velocity	(E/e′)	was	increased	in	obese	rats	
(Figure	1D).	Surprisingly,	both	for	the	reduced	cardiac	index	and	the	
increased	E/e’	ratios,	no	 interaction	among	the	comorbidities	was	
observed.
In	contrast	to	the	functional	findings,	which	were	principally	af-
fected	by	obesity,	RNAseq	revealed	that	DS-induced	hypertension	
caused	the	most	predominant	transcriptional	variance	(Figure	1E).	
In	cardiac	tissue	of	placebo-treated	obese	vs	placebo-treated	lean	
rats	and	DS-treated	obese	vs	DS-treated	 lean	 rats,	 a	 total	of	410	
and	146	genes	were	differentially	 expressed	 (FDR	<	0.1),	 respec-
tively	 (Figure	 1F-G,	 Table	 S2-S3).	 Conversely,	 in	 DS-treated	 lean	
rats	vs	placebo-treated	lean	rats	and	DS-treated	obese	rats	vs	pla-
cebo-treated	obese	rats,	a	total	of	1258	and	1504	genes	were	dif-
ferentially	expressed	 (FDR	<	0.1),	 respectively	 (Figure	1H-I,	Table	
S4-S5).
3.2 | Mitochondrial gene expression and apoptosis
Analyses	of	 transcription	profiles	with	 Ingenuity	Pathway	Analysis	
(IPA)	 indicated	 that	both	 risk	 factors	had	substantial,	 yet	opposite	
effects	 on	 genes	 involved	 in	 mitochondrial	 function.	 In	 placebo-
treated	rats,	enzymes	involved	in	fatty	acid	metabolism	and	oxida-
tive	phosphorylation	were	up-regulated	in	the	obese	vs	lean	group	
(Figure	2A-B).	In	contrast,	both	lean	and	obese	DS-treated	rats	had	
an	overall	down-regulation	vs	placebo-treated	rats	of	genes	involved	
in	oxidative	phosphorylation,	a	phenomenon	often	observed	in	mi-
tochondrial	dysfunction	(Figure	2A	and	2D).14,15
IPA	predicted	that	the	transcriptional	regulator	Krüppel-like	fac-
tor	15	(KLF15),	which	has	been	described	as	a	key	regulator	induc-
ing	mitochondrial	fatty	acid	substrate	usage,16	was	the	most	active	
upstream	 regulator	 in	 placebo-treated	 obese	 vs	 lean	 rats	 (overlap	
P	=	2.66E-13/Z-score	=	2.95).	 Interestingly,	 it	was	among	the	most	
suppressed	 regulators	 in	DS-treated	 rats	 (overlap	P	 =	 5.37E-14/Z-
score=−3.97	and	overlap	P	=	7.73E-17/Z-score=−3.70	in	lean	+	DS	vs	
TA B L E  1  Model	characteristics	at	26	wk	of	age
 
Lean Lean + DS Obese Obese + DS P‐values
(n = 6) (n = 7) (n = 6) (n = 7) Obesity DS Interaction
Tibia	length	(mm) 40.8	±	0.5 40.0	±	0.4 38.1	±	0.4a 39.1	±	0.6 <.05 .93 .05
Body	weight	(g) 443	±	9 417	±	10 584	±	13a 607	±	10b <.05 .91 <.05
Cholesterol	(mM) 2.2	±	0.1 2.1	±	0.1 8.2	±	0.8a 9.1	±	0.7b <.05 .46 .34
Triglycerides	(mM) 1.5	±	0.2 1.1	±	0.2 23.8	±	4.0a 20.5	±	2.5b <.05 .44 .53
Glucose	(mM) 9.9	±	0.5 9.1	±	0.5 22.5	±	2.6a 14.0	±	1.6d <.05 <.05 <.05
Natriuresis	(μmol/d) 1484	±	191 10502	±	1126c 3260	±	422 14749	±	1463b,d <.05 <.05 .213
Natriuresis	
(μmol/d/100	g)
338	±	46 2546	±	300c 544	±	71 2419	±	213d .83 <.05 .378
SBP	(mm	Hg) 153	±	3 179	±	4c 150	±	1 213	±	5b,d <.05 <.05 <.05
Heart	rate	(bpm) 381	±	9 362	±	8 308	±	9a 292	±	6b <.05 <.05 .81
SV	(μL) 212	±	19 217	±	23 178	±	19 187	±	19 .13 .71 .90
CO	(mL/min) 81	±	7 79	±	8 55	±	6 55	±	5 <.05 .87 .92
CI	(mL/min/100	g) 18.2	±	1.6 18.7	±	1.7 9.5	±	1.2a 9.0	±	0.9b <.05 .99 .73
EF	(%) 73	±	2 70	±	3 65	±	1a 59	±	2b,d <.05 <.05 .48
E/e’ 15.9	±	0.9 17.5	±	0.6 20.5	±	0.6a 22.9	±	0.7b,d <.05 <.05 .55
LVW	(mg) 909	±	27 1139	±	64 1172	±	66 1490	±	116b,d <.05 <.05 .58
HW	(LV	+	RV;	mg) 1338	±	32 1459	±	48 1474	±	41 1684	±	50b,d <.05 <.05 .32
Note: Values	are	mean	±	SEM,	followed	by	main	effect-	(effect	obesity/	effect	DS)	and	interaction	p-values,	as	determined	by	2-way	ANOVA.
Abbreviations:	100g,	100g	body	weight;	CI,	cardiac	index;	CO,	cardiac	output;	d,	day;	HW,	heart	weight;	LVW,	left	ventricle	weight;	RV,	right	ventri-
cle;	SBP,	systolic	blood	pressure;	SV,	stroke	volume;	TL,	tibia	length.
aObese	vs	lean,	
bObese	+	DS	vs	lean	+	DS,	
cLean	+	DS	vs	lean,	
dObese	+	DS	vs	obese	P < .05. 
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F I G U R E  2  Pathway	analysis	and	mitochondrial	gene	expression	(A)	Graphical	visualization	of	3	most	affected	pathways	according	
to	Ingenuity	Pathway	Analysis	(orange	and	blue	represent	pathway	activation	and	repression,	respectively,	grey	represents	no	direction	
available).	(B)	Schematic	presentation	of	RNAseq	data	for	differentially	expressed	genes	involved	in	fatty	acid	oxidation,	(C)	KLF15-induced	
transcription	(D)	and	oxidative	phosphorylation.	Shown	is	a	colour-based	representation	of	the	reads	per	kilobase	million,	relative	to	the	
average	expression	in	the	lean	group,	for	each	individual	rat	(orange	and	blue	represent	increased	and	decreased	expression,	relatively).	(E)	
QPCR	analysis	of	oxidative	stress	marker	CAT.	n	=	5-7,	*	P	<	.05.	(F)	Analysis	of	urinary	TBARS	excretion	as	marker	of	systemic	oxidative	
stress.	n	=	6-7,	*	P < .05
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lean	 and	obese	+	DS	 vs	 obese,	 respectively;	 Figure	2C,	 Table	 S6-
S8).	qPCR	analysis	of	established	KLF15	 targets	Hydroxyacyl-CoA	
Dehydrogenase	 Trifunctional	Multienzyme	 Complex	 Subunit	 Beta	
(HADHB),	Acyl-CoA	Dehydrogenase	Medium	Chain	 (ACADM)	and	
2,4	Dienoyl-CoA	reductase	(DECR1),	substantiated	this	observation	
(Figure	S1).
RNAseq	data	also	widely	supported	the	DS-induced	down-reg-
ulation	of	genes	coding	 for	enzymes	 in	oxidative	phosphorylation,	
equally	 affecting	 the	 different	 complexes	 of	 the	 electron	 trans-
port	 chain	 (Figure	 2D).	 Remarkably,	 DS-induced	 down-regulation	
of	 genes	 involved	 in	 oxidative	 phosphorylation	was	 not	 accompa-
nied	by	elevated	transcription	of	oxidative	stress-responsive	factor	
Catalase	(CAT),	whereas	the	increased	transcription	of	fatty	acid	ox-
idation	(FAO)	genes	in	placebo-treated	obese	rats	on	the	other	hand	
was	associated	with	elevated	CAT	expression	(Figure	2E).	Systemic	
oxidative	stress,	as	measured	by	urinary	excretion	of	thiobarbituric	
acid	reactive	substances	(TBARS),	followed	a	similar	pattern,	show-
ing	an	elevation	in	placebo-treated	obese	rats	(Figure	2F).
The	 adaptations	 in	 transcription	 of	 mitochondrial	 genes	
raised	 the	 question	 whether	 this	 led	 to	 programmed	 cell	 death.	
Histological	analysis	of	activated	Caspase	3,	a	marker	of	early	apop-
tosis,	indicated	no	significant	changes	in	sub-endocardial	apoptosis	
(Figure	 S2A	 and	 C),	 although	 the	 apoptotic	 effect	 of	 DS-induced	
hypertension	showed	a	trend	(P	=	 .05;	Table	S9).	A	similar	pattern	
was	 observed	 after	 labelling	 cells	 for	 late	 apoptosis,	 using	 termi-
nal	deoxynucleotidyl	transferase	dUTP	nick	end	labelling	(TUNEL).	
Individually	no	differences	were	observed,	although	overall	DS-in-
duced	hypertension	stimulated	apoptosis	(Figure	S2B	and	D,	Table	
S9).	Noteworthy,	 the	apoptotic	cells	were	predominantly	 found	 in	
patchy	regions	(Figure	S2E).
F I G U R E  3  Cardiomyocyte	hypertrophy	and	foetal	gene	expression	(A)	Typical	examples	and	(B)	quantification	of	histological	staining	for	
cardiac	hypertrophy	(Gomori).	n	=	4-6,	*	P	<	.05.	C,	QPCR	analysis	of	cardiac	transcription	of	hypertrophy	markers	MYH6,	MYH7	and	NPPA,	
(D)	regulators	of	cytoplasmic	Ca2+	levels	SERCA2A,	PLN	and	ATP1A2	and	(E)	transcriptional	target	of	Ca2+-induced	NFAT	activation	RCAN1.	
n	=	5-7,	*	P < .05
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3.3 | Cardiomyocyte hypertrophy and foetal 
gene expression
To	get	a	better	insight	in	myocardial	hypertrophy	in	response	to	the	co-
morbidities,	 the	cross-sectional	area	of	 individual	cardiomyocytes	was	
studied.	Presence	of	both	comorbidities	led	to	significant	cardiomyocyte	
hypertrophy	(Figure	3A-B).	In	contrast	to	the	HW	and	LVW,	which	were	
affected	 by	 both	 DS-induced	 hypertension	 and	 obesity	 individually,	
obesity	was	associated	with	an	elevated	cellular	cross-sectional	area,	but	
no	contribution	of	DS-induced	hypertension	was	observed	(Table	S9).
Transcription	 of	myosin	 heavy	 chain	 α	 (MYH6)	 and	 β	 (MYH7),	
defined	markers	for	myocardial	hypertrophy,17	resembled	this	pre-
dominant	 obesity-induced	 effect	 on	 cardiac	 remodelling.	 Obesity	
triggered	a	down-regulation	of	MYH6	and	an	up-regulation	MYH7	
(Figure	3C).	DS-induced	hypertension	also	reduced	the	expression	
of	 MYH6,	 though	 the	 effect	 size	 was	 more	 than	 two	 fold	 lower	
than	 that	 of	 obesity	 and	 appeared	 additive,	 not	 synergistic	 (Table	
S9).	Atrial	natriuretic	peptide	(NPPA)	on	the	other	hand,	like	MYH6	
and	MYH7	a	well-described	hypertrophy	marker,	was	up-regulated	
solely	in	DS-treated	rats.
Transcriptional	analysis	demonstrated	that	expression	of	sarco/
endoplasmic	 reticulum	 Ca2+-ATPase	 (SERCA2A)	 and	 phospholam-
ban	(PLN),	both	involved	in	calcium	reuptake	by	the	sarcoplasmic	re-
ticulum	during	diastole,	was	affected	as	well.	SERCA2A	expression	
was	 lowered	by	both	 comorbidities,	whereas	PLN	appeared	 to	be	
principally	affected	by	DS-induced	hypertension	(Figure	3D).	In	line	
with	SERCA2A,	transcription	of	ATPase,	Na+/K+	transporting	alpha	
2	 (ATP1A2),	was	significantly	 lower	 in	response	to	obesity	and	DS	
treatment.	Of	note,	both	for	SERCA2A	and	ATP1A2,	there	was	no	
interaction	of	the	comorbidities	 (Figure	3D,	Table	S9).	Remarkably,	
regulator	of	calcineurin	1	(RCAN1),	which	is	a	direct	Ca2+-dependent	
transcriptional	 target	of	nuclear	 factor	of	activated	T	cells	 (NFAT),	
was	solely	up-regulated	in	placebo-treated	obese	rats,	whereas	the	
opposite	response	was	induced	by	DS	(Figure	3E).
3.4 | Capillary density
To	 evaluate	whether	DS-induced	 hypertension	 and	 obesity	 affect	
capillary	density,	a	lectin	staining	was	applied	on	LV	cross	sections.	
Surprisingly,	no	differences	were	observed	in	any	of	the	conditions	
(Figure	4A-B).	The	absence	of	microvascular	adaptations	was	sub-
stantiated	by	transcription	 levels	of	well-known	modulators	of	mi-
crovascular	stability	Angiopoietin	1	and	2	 (ANGPT1	and	ANGPT2,	
respectively),	 and	 hypoxia-associated	 factor	 Vascular	 Endothelial	
Growth	 Factor	 A	 (VEGFA).	 Transcription	 of	 vascular	 destabilizing	
factors	ANGPT2	and	VEGFA	was	not	affected	by	the	comorbidities	
(Figure	4C).	Interestingly,	transcription	of	ANGPT1,	which	promotes	
vascular	stability,	was	 increased	in	placebo-treated	obese	rats,	but	
not	in	DS-treated	obese	rats	vs	their	respective	lean	counterparts.
3.5 | Inflammatory cells
To	assess	the	impact	of	DS-induced	hypertension	and	obesity	on	the	
cardiac	 inflammatory	 state,	 presence	 of	 CD3+	 T	 cells	 and	CD68+	
F I G U R E  4  Capillary	density.	(A)	Typical	examples	and	(B)	quantification	of	LV	microvasculature	(Lectin).	n	=	4-6,	*	P	<	.05.	(C)	QPCR	
analysis	of	cardiac	transcription	of	factors	involved	in	vascular	remodelling	ANGPT1,	ANGPT2	and	VEGFA.	n	=	5-7,	*	P < .05
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macrophages	was	 evaluated.	 The	 number	 of	 CD3+	 T	 cells,	 repre-
senting	adaptive	immunity,	was	low	and	not	affected	by	obesity	or	
DS-induced	hypertension	(Figure	5A	and	5C,	Table	S9).	In	contrast,	
presence	 of	 CD68+	 macrophages,	 representing	 innate	 immunity,	
was	 markedly	 increased	 by	 DS-induced	 hypertension	 (Figure	 5B	
and	5D,	Table	S9).	Obesity	alone	had	no	effect,	but	in	combination	
with	DS-induced	hypertension	it	significantly	increased	macrophage	
presence,	 showing	a	 synergistic	 trend	 (interaction	P	 =	 .09).	 In	 line	
with	the	observed	DS-induced	apoptosis,	macrophage	presence	was	
mostly	seen	in	patchy	clusters	(Figure	5E).
3.6 | Fibrosis and TGFβ signalling
To	 evaluate	 the	 impact	 of	 the	 comorbidities	 on	 the	 development	
and	progression	of	fibrosis,	collagen	deposition	was	measured.	Picro	
Sirius	Red	positivity	in	the	placebo-treated	obese	ZSF1	rats	was	not	
different	from	the	placebo-treated	lean	rats.	In	contrast,	DS-induced	
hypertension	 triggered	 a	 profound	 fibrotic	 response.	 The	 DS-in-
duced	fibrosis	appeared	to	be	aggravated	by	obesity,	although	no	sig-
nificant	interaction	was	observed	(interaction	P	=	.31;	Figure	6A-B,	
Table	 S9).	 These	 findings	 were	 substantiated	 by	 qPCR	 validation	
of	collagen	1α1	(COL1A1),	collagen	3α1	(COL3A1),	and	fibronectin	
(FN1)	expression.	Obesity	alone	had	no	effect,	whereas	DS-induced	
hypertension	enhanced	their	transcription.	This	DS-induced	up-reg-
ulation	was	aggravated	in	the	presence	of	obesity	(Figure	6C),	and	
significant	synergy	was	observed	for	COL3A1	and	FN1	 (Table	S9).	
Based	on	the	overall	transcription	profiles,	IPA	predicted	high	activ-
ity	of	transforming	growth	factor	(TGF)-β1	(overlap	P	=	2.81E-11/Z-
score	=	4.01	and	overlap	P	=	2.95E-31/Z-score	=	6.24	in	lean	+	DS	
vs	lean	and	obese	+	DS	vs	obese,	respectively)	and	TGFβ2	(overlap	
P	=	2.14E-4/Z-score	=	1.75	and	overlap	P	=	1.82E-6/Z-score	=	2.51	
in	lean	+	DS	vs	lean	and	obese	+	DS	vs	obese,	respectively)	signalling	
F I G U R E  5   Inflammatory	cells.	(A)	Typical	examples	of	immunological	staining	for	LV	T	cell	(CD3)	and	(B)	macrophage	(CD68)	presence.	
Positively	labelled	cells	are	depicted	with	an	arrowhead.	(C)	Quantification	of	immunological	staining	for	LV	T	cell	(CD3)	and	(D)	macrophage	
(CD68)	presence	per	image	field.	n	=	4-7,	*	P	<	.05.	E,	Magnified	visualization	of	immunological	CD68	labelling	in	DS-treated	obese	rats,	
illustrative	for	the	observed	DS-induced	increase	in	apoptosis	seen	in	regions	with	high	cellular	density
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in	the	hearts	of	DS-treated	vs	placebo-treated	rats	(Table	S10-S11).	
This	 predicted	 activation	was	 accompanied	 by	 transcriptional	 up-
regulation	 of	 TGFβ1	 and	TGFβ2	 (Figure	 6D)	 upon	DS-induced	 hy-
pertension.	Moreover,	 in	 addition	 to	 COL1A1,	 COL1A3	 and	 FN1,	
various	TGFβ	target	genes,	including	periostin	(POSTN)	and	osteo-
pontin	1	 (SPP1)	were	up-regulated	 (Figure	6E),	of	which	 the	 latter	
has	recently	been	demonstrated	to	have	predictive	value	for	clinical	
outcome	in	HFpEF.18
4  | DISCUSSION
In	 line	 with	 previous	 reports,12,13	 ZSF1	 rats	 with	 a	 homozy-
gous	 leptin	 receptor	 mutation	 in	 our	 current	 study	 presented	
with	 metabolic	 derangements,	 including	 elevated	 body	 weight,	
hypercholesteremia,	 hyperglycaemia	 and	 hypertriglyceridemia.	
As	 anticipated,	 DS	 treatment	 triggered	 severe	 hypertension	 in	
both	 lean	 and	 obese	 ZSF1	 rats,	 and	 the	 combination	 of	 these	
factors	enabled	us	to	study	if	and	how	obesity	and	hypertension	
contribute	to	the	development	of	diastolic	dysfunction	at	a	func-
tional,	 histological	 and	 transcriptional	 level.	 From	 this	 study,	we	
can	 conclude	 that	 (a)	 obesity-associated	 derangements	 had	 the	
most	 predominant	 effect	 on	 development	 of	 diastolic	 dysfunc-
tion,	with	no	synergy	observed	between	obesity	and	DS-induced	
hypertension;	 (b)	 obesity	 also	 predominantly	 affected	 LV	 hyper-
trophic	 remodelling,	which	was	 associated	with	 increased	 foetal	
gene	expression	and	Ca2+-mediated	transcription;	(c)	capillary	rar-
efaction	was	 absent	 in	 all	 conditions,	whereas	 inflammation	and	
fibrosis	 occurred	 in	 response	 to	 DS-induced	 hypertension,	 with	
partial	synergy	observed	if	in	combination	with	obesity;	and	that	
F I G U R E  6  Fibrosis	and	TGFβ	signalling.	(A)	Typical	examples	and	(B)	quantification	of	histological	staining	for	cardiac	collagen	deposition	
(Picro	Sirius	Red).	n	=	6-7,	*	P	<	.05.	(C)	QPCR	analysis	of	cardiac	transcription	of	extracellular	matrix	components	COL1A1,	COL3A1	and	
FN1,	(D)	activators	of	TGFβ	signalling	TGFβ1	and	TGFβ2	and	(E)	transcriptional	targets	of	TGFβ	signalling	POSTN	and	SPP1.	n	=	5-7,	*	P < .05
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(d)	 obesity	 stimulated	enhanced	expression	of	 genes	 involved	 in	
FAO,	whereas	DS	treatment	led	to	an	overall	down-regulation	of	
genes	 involved	 in	 oxidative	 phosphorylation,	 implying	 that	 the	
comorbidities	triggered	different	mitochondrial	responses.	These	
findings	 do	 not	 support	 our	 initial	 hypothesis	 and	 illustrate	 im-
portant	phenotypical	differences	 in	comorbidity-induced	cardiac	
adaptation.
Diastolic	 dysfunction,	 or	more	 specifically,	 impaired	 active	 re-
laxation	and	reduced	LV	passive	compliance	leading	to	increased	LV	
diastolic	pressures,	is	a	phenotypical	hallmark	of	HFpEF.19,20	A	well-
defined	echocardiographic	parameter	to	define	presence	of	diastolic	
dysfunction	 is	 the	E/e’	 ratio,21	which	was	 significantly	 elevated	 in	
both	placebo-	and	DS-treated	obese	rats,	compared	with	their	lean	
counterparts.	Similarly,	obesity	was	strongly	associated	with	a	lower	
CO.	Interestingly,	DS-induced	hypertension	had	no	effect	on	CO	and	
only	a	minor	effect	on	E/e’	ratio.	Surprisingly,	no	functional	interac-
tion	was	observed	between	the	comorbidities.	These	findings,	indi-
cating	a	relatively	mild	contribution	of	hypertension	on	development	
and	progression	of	diastolic	dysfunction	and	suggesting	a	more	pro-
nounced	causal	relation	with	metabolic	derangements,	could	explain	
why	antihypertensive	treatment	thus	far	has	not	established	a	major	
survival	benefit	in	HFpEF	patients.11
The	 lowering	of	CO	 induced	by	obesity	was	principally	 the	 re-
sult	of	a	lower	heart	rate,	which	is	consistent	with	diabetes-induced	
lowering	 of	 resting	 heart	 rates,22	 while—surprisingly—stroke	 vol-
ume	was	maintained	even	when	both	obesity	and	DS	were	present.	
Stroke	volume	was	likely	maintained	as	a	result	of	the	bradycardia-
induced	increase	 in	diastolic	filling	time,	thereby	compensating	for	
the	impaired	relaxation	and	the	presence	of	concentric	hypertrophy.	
In	addition	to	stroke	volume,	 it	has	previously	been	demonstrated	
that	dynamics	in	heart	rate	can	also	affect	indices	of	diastolic	func-
tion,	though	E/e’,	which	was	our	primary	readout	for	diastolic	func-
tion,	does	not	appear	to	be	affected	by	differences	in	heart	rate.23 In 
addition	to	E/e’	and	CO,	EF	was	minimally	affected	by	either	obesity	
or	DS-induced	 hypertension.	 Currently,	 there	 are	 no	 clear	 cut-off	
values	for	preserved	or	reduced	EF	in	rats.	However,	baseline	EF	de-
termined	by	echocardiography	in	healthy	male	Sprague-Dawley	rats	
is	64	±	7%,24	suggesting	that	the	lowest	EF	of	59	±	2%,	as	observed	
for	the	DS-treated	obese	rats,	could	be	considered	as	a	preserved	
EF.
In	 the	ZSF1	 rats,	 total	HW	and	LVW	reached	statistical	 signif-
icance	only	when	both	comorbidities	were	present,	 although	vari-
ance	was	individually	affected	both	by	obesity	and	DS.	Remarkably,	
variance	in	cardiomyocyte	cross-sectional	area	was	solely	affected	
by	obesity,	suggesting	that	the	effect	of	DS	treatment	on	HW	might	
at	least	in	part	be	secondary	to	a	cellular	hypertrophy-independent	
process,	such	as	fibrosis.	Noteworthy,	in	none	of	the	hypertrophy-
related	parameters,	interaction	was	observed	between	hypertension	
and	 obesity.	 Transcriptional	 analysis	 supported	 the	 predominant	
obesity-induced	myocardial	maladaptation,	which	generally	occurs	
in	 the	presence	of	 reinitiated	 foetal	gene	expression	and	elevated	
Ca2+-induced	 transcription.17,25	 In	 that	 regard,	 a	 clear	 obesity-
driven	switch	from	MYH6	to	MYH7	was	noticed,	as	well	as	elevated	
transcription	of	RCAN1,	a	defined	target	gene	of	the	Ca2+-respon-
sive	transcription	factor	NFAT.26	The	RNAseq	data	also	underscored	
the	 notion	 that	 diastolic	 dysfunction-associated	 hypertrophy	 can	
develop	in	absence	of	a	severe	increase	in	cardiac	afterload.	In	the	
ZSF1	rats,	blood	pressure-	and	wall	stretch-responsive	factor	NPPA	
27	was	exclusively	up-regulated	 in	DS-treated	rats,	whereas	 in	pla-
cebo-treated	obese	rats	with	an	apparent	absence	of	elevated	wall	
stretch,	hypertrophy	developed.	As	NPPA	has	been	demonstrated	
to	inhibit	NFAT	activation,25	this	DS-induced	up-regulation	of	NPPA	
could	explain	why	RCAN1	was	not	up-regulated	in	DS-treated	rats,	
even	 though	 crucial	 Ca2+-handling	 genes	 (ATP1A2,	 SERCA2A	 and	
PLN)	were	dysregulated	upon	DS-induced	hypertension.	Besides	its	
role	as	 second	messenger	 in	various	 signal	 transduction	cascades,	
Ca2+—and	its	removal	from	the	cytosol—plays	an	 important	role	 in	
active	 relaxation.	 As	 diastolic	 dysfunction	was	most	 prominent	 in	
obese	animals,	yet	both	obesity	and	DS	treatment	lowered	the	ex-
pression	of	several	key	Ca2+-handling	genes,	our	results	suggest	that	
in	this	model	impaired	passive	rather	than	active	relaxation	contrib-
uted	to	the	observed	diastolic	dysfunction.
In	addition	to	cardiomyocyte	hypertrophy,	it	has	been	proposed	
that	HFpEF-associated	comorbidities	can	induce	systemic	inflamma-
tion,	leading	to	endothelial	inflammation	and	oxidative	stress,	favour-
ing	monocyte	extravasation,	fibrosis	and	microvascular	rarefaction.2 
Fibrosis	is	suspected	to	result	from	monocyte-induced	TGFβ	secre-
tion,	and	to	actively	contribute	to	LV	stiffening,28	whereas	a	reduc-
tion	in	capillary	density	may	impair	oxygen	delivery,	limiting	systolic	
and	diastolic	reserve	function,29	yet	could	also	lower	NO	availability	
which	contributes	 to	passive	 stiffness	and	LV	hypertrophy	via	 im-
paired	Protein	Kinase	G	activation.2	In	LV	sections	from	HFpEF	pa-
tients,	indeed	fibrosis	and	a	lower	capillary	density	were	observed,29 
but,	 in	 line	with	our	previous	study,13	no	capillary	 rarefaction	was	
observed	in	any	of	the	ZSF1	rats.	From	the	current	study,	it	cannot	
be	excluded	that	loss	of	capillaries	develops	at	a	later	stage	of	the	dis-
ease,	although	these	data	do	suggest	that	it	is	not	a	prerequisite	for	
the	development	of	diastolic	dysfunction.	Interestingly,	even	in	the	
absence	of	capillary	rarefaction,	a	clear	inflammatory	and	fibrotic	re-
sponse	was	observed.	In	contrast	to	the	obesity-driven	diastolic	dys-
function	and	cardiomyocyte	hypertrophy,	inflammation	and	fibrosis	
predominantly	occurred	in	DS-induced	hypertensive	rats.	It	has	pre-
viously	been	shown	that	resident	cardiac	macrophages	can	respond	
to	hypertension	by	activation	of	pro-inflammatory	signalling,30 due 
to	 exposure	 to	 altered	 mechanical	 forces.31	 Additionally,	 DS-in-
duced	 activation	 of	mineralocorticoid	 receptors	 could	 also	 trigger	
cardiac	inflammation	and	fibrosis,	independent	of	hypertension,32,33 
implying	that	multiple	mechanisms	could	orchestrate	the	observed	
response	in	the	hypertensive	rats.	In	placebo-treated	obese	rats,	no	
inflammatory	or	fibrotic	responses	were	observed,	suggesting	that	
the	 increased	urinary	TBARS	excretion	 in	 these	 rats	was	 presum-
ably	 not	 derived	 from	 vascular	 and	 neutrophilic	 NADPH-induced	
oxidative	stress.34	 Interestingly,	obesity	did	significantly	aggravate	
DS-induced	 macrophage	 presence	 and	 triggered	 up-regulation	 of	
many	 extracellular	matrix	 components	with	 a	 TGFβ	 signature,35,36 
suggesting	 putative	 interaction	with	DS-induced	 hypertension	 for	
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this	 particular	 aspect	 of	 LV	 adaptation.	 However,	 obesity	 and	DS	
treatment	also	showed	mild	 interaction	in	elevation	of	the	systolic	
blood	pressure.	Considering	that	elevated	salt	sensitivity	has	often	
been	demonstrated	for	obesity,37-39	this	elevation	of	SBP	is	not	an	
unexpected	 interaction.	 In	 fact,	 this	 may	 represent	 an	 important	
mechanism	through	which	interaction	between	these	comorbidities	
occurs.	Although	 the	elevated	body	mass	 in	obese	animals	mainly	
consists	 of	 fat,	 the	 contribution	 of	 which	 to	 extracellular	 fluid	 is	
limited	compared	to	non-fat	tissue,	 the	normalized	urinary	sodium	
excretion	data	suggests	that	the	observed	synergy	does	not	simply	
develop	via	elevated	food	and	thus	increased	salt	intake	in	the	obese	
rats.	Nonetheless,	 from	 these	data	 it	 cannot	be	excluded	 that	 the	
observed	increase	in	inflammation	and	fibrosis,	the	only	parameters	
for	which	 significant	 interaction	was	observed,	was	mainly	 hyper-
tension-driven.	However,	the	latter	would	plead	the	case	for	limited	
synergy	between	obesity	and	hypertension	even	more.
The	broad	range	of	our	analysis	enabled	us	to	dissect	how	func-
tional	differences	in	cardiac	response	to	obesity-associated	aberra-
tions	 and	DS-induced	hypertension	were	 reflected	by	 the	distinct	
transcription	profiles.	By	comparing	the	transcriptome	of	placebo-
treated	obese	rats	with	that	of	placebo-treated	lean	rats,	the	most	
abundant	response	came	from	elevated	expression	of	genes	encod-
ing	enzymes	 involved	 in	FAO.	Although	cardiac	hypertrophy	 is	as-
sociated	with	decreased	FAO	and	increased	glucose	metabolism,40 
this	finding	was	not	completely	unexpected	considering	the	diabetic	
background	of	these	rats.41	Nonetheless,	increased	FAO	is	also	ev-
ident	 in	HFpEF	patients,42	and	due	to	the	 lower	oxygen	efficiency	
compared	with	 glucose	metabolism,43	 this	 could	 result	 in	 a	 lower	
ATP	bioavailability,	which	can	contribute	to	hampered	energy-con-
suming	diastolic	relaxation.44	The	increased	FAO,	which	may	partly	
occur	 in	 peroxisomes,45	 might	 also	 be	 causally	 related	 to	 the	 ob-
served	 elevation	 of	 oxidative	 stress.	 As	 peroxisomes	 lack	 a	 respi-
ratory	chain,	electrons	from	FADH2	are	transferred	directly	to	O2,	
generating	H2O2	and	heat.
45	In	line	with	previous	studies,46	obesity	
appeared	to	induce	peroxisomal	FAO,	as	illustrated	by	higher	expres-
sion	of	peroxisomal-specific	Acyl-Coenzyme	A	Oxidase	1	(ACOX1)	
and	Acyl-CoA	Dehydrogenase	Very	Long	Chain	(ACADVL).	The	up-
regulation	of	CAT	in	placebo-treated	obese	rats,	which	is	predomi-
nantly	involved	in	peroxisomal	H2O2	conversion,
45	substantiates	the	
putative	peroxisomal	source	of	oxidative	stress.
Strikingly,	when	transcription	profiles	of	DS-treated	rats	were	
compared	 with	 those	 of	 placebo-treated	 rats,	 an	 overall	 down-
regulation	 of	 factors	 involved	 in	 oxidative	 phosphorylation	 was	
observed,	negatively	modulating	both	 fatty	acid	and	glucose	ox-
idation.	Others	have	shown	that	down-regulation	of	only	a	mini-
mal	number	of	genes	involved	in	oxidative	phosphorylation	could	
induce	mitochondrial	dysfunction.14,15	Mitochondrial	dysfunction	
is	 causally	 related	 to	myocardial	 cell	 death,47,48	which	might	 ex-
plain	 the	 effect	 of	 DS	 on	 sub-endocardial	 TUNEL	 labelling.	 The	
relation	between	hypertension	 and	mitochondrial	 dysfunction	 is	
well	 described.49,50	 However,	 the	 present	 findings	 illustrate	 the	
different	effects	of	two	HFpEF	comorbidities	on	energy	homeo-
stasis,	 indicating	 that	 in	 obese	 rats	 the	mechanisms	 involved	 in	
metabolic	derangements,	with	a	putative	 role	 in	development	of	
diastolic	dysfunction,	are	dependent	on	the	presence	or	absence	
of	hypertension.	These	observations	emphasize	the	need	for	thor-
ough	phenotypical	characterization	of	HFpEF	patients.51
In	 summary,	 the	 present	 study	 shows,	 to	 our	 knowledge	 for	
the	 first	 time,	 how	 obesity	 and	 hypertension	 contribute	 to	 the	
development	of	diastolic	dysfunction.	Our	data	show	that	 intrin-
sic	metabolic	 derangements	 in	ZSF1	 rats	 have	 the	most	 evident	
effect	on	development	of	diastolic	dysfunction.	However,	from	a	
mitochondrial,	fibrotic,	and	inflammatory	point	of	view,	the	pres-
ence	of	 severe	hypertension	 appears	 to	have	 a	major	 impact	on	
disease	progression.	When	considering	therapeutic	interventions,	
it	 thus	 would	 seem	 extremely	 important	 to	 anticipate	 potential	
pathophysiological	 differences	 among	HFpEF	patients	 that	were	
thus	 far	 grouped	 together	 based	 on	 the	 common	 denominator	
‘preserved	EF’.	For	 instance,	aiming	for	a	switch	from	fatty	acids	
towards	more	oxygen-efficient	glucose	metabolism,	as	was	previ-
ously	suggested	in	HFpEF,52	might	provide	an	opening	with	prom-
ising	therapeutic	potential	 in	obese	patients,	but	may	well	be	far	
less	effective	when	applied	to	HFpEF	patients	with	hypertension-
induced	mitochondrial	dysfunction.
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